


CLAIMS

1. A compound as represented by formula I, and a pharmaceutically acceptable salt or prodrug thereof,



Formula I

wherein, R₁ is selected from H, amino, hydroxy or sulfydryl, R₂ is selected from H, amino, hydroxy, sulfydryl or $-(CH_2)_nNHR_8$, wherein $n=1-5$, R₈ is H or C1-3 alkyl; R₃ is selected from H or C1-6 alkyl; R₄, R₅ and R₆ are each independently selected from H, halogen, C1-6 alkyl or halogen substituted alkyl; and R₇ is selected from H, C1-6 alkyl or halogen;

or, R₂ and R₃ together with the carbon atom connecting them form substituted or unsubstituted 5- or 6-membered ring having 1 to 2 heteroatoms, wherein the heteroatoms are N, O or S, and the substituent is C1-6 alkyl.

2. The compound and the pharmaceutically acceptable salt or prodrug thereof according to claim 1, wherein R₂ is selected from H, amino or $-(CH_2)_nNHR_8$, wherein $n=1-3$, R₈ is H or C1-2 alkyl; R₃ is selected from H or C1-2 alkyl; R₄, R₅ and R₆ are each independently selected from halogen, C1-2 alkyl or halogen substituted alkyl; and R₇ is selected from H or halogen;

or, R₂ and R₃ together with the carbon atom connecting them form substituted or unsubstituted 5- or 6-membered ring having 1 nitrogen atom, wherein the substituent is C1-3 alkyl.

3. The compound and the pharmaceutically acceptable salt or prodrug thereof according to claim 1, wherein R₂ is selected from H, amino or $-(CH_2)_nNHR_8$, wherein $n=1-3$, R₈ is H or C1-2 alkyl; R₃ is selected from H or C1-2 alkyl; R₄, R₅ and R₆ are each independently selected from halogen, C1-2 alkyl or halogen substituted alkyl; and R₇ is selected from H or halogen;


or, R₂ and R₃ together with the carbon atom connecting them form substituted or unsubstituted 5- or 6-membered ring having 1 nitrogen atom, wherein the substituent is C1-3 alkyl,

the halogen is F or Cl.


4. The compound and the pharmaceutically acceptable salt or prodrug thereof according to claim 2 or 3, wherein R_2 is selected from amino or $-(CH_2)_nNHR_8$; or, R_2 and R_3 together with the carbon atom connecting them form substituted or unsubstituted 5- or 6-membered ring having 1 nitrogen atom, wherein the substituent is C1-3 alkyl.

5. The compound and the pharmaceutically acceptable salt or prodrug thereof according to claim 2 or 3, wherein at least one of R_1 , R_2 and R_3 is amino, and the rest are H; R_4 , R_5 and R_6 are the same and are selected from F or Cl; and R_7 is H.

6. The compound and the pharmaceutically acceptable salt or prodrug thereof according to any one of claims 1-5, wherein the compound is one of the following compounds:



15 2-1 , 2-2 , 2-3 ,



2-4 , 2-5 .

20 7. Use of the compound and the pharmaceutically acceptable salt or prodrug thereof according to any one of claims 1-6 in the preparation of a medicament for inhibiting the abnormal proliferation of angiogenesis or treating diseases associated with the abnormal proliferation of angiogenesis.

8. Use according to claim 7, wherein the medicament for inhibiting the abnormal proliferation of angiogenesis is VEGFR2 inhibitor.

9. Use according to claim 7, wherein the medicament for inhibiting the abnormal proliferation of angiogenesis is a medicament against ocular angiogenesis, and the diseases associated with the abnormal proliferation of angiogenesis are diseases associated with ocular angiogenesis.

10. Use according to claim 7, wherein the medicament for inhibiting the abnormal proliferation of angiogenesis is choroidal angiogenesis inhibitor, and the diseases associated with the abnormal proliferation of angiogenesis are diseases associated with choroidal angiogenesis.

11. Use according to claim 9 or 10, wherein the medicament for inhibiting the abnormal proliferation of angiogenesis is a medicament for treating or preventing wet macular degeneration, diabetic retinopathy or neovascular glaucoma, and the diseases associated with the abnormal proliferation of angiogenesis are wet macular degeneration, diabetic retinopathy or neovascular glaucoma.

12. Use of the compound and a pharmaceutically acceptable salt or prodrug thereof according to any one of claims 1-6 in the preparation of a protein kinase inhibitor medicament or in the preparation of a medicament for treating diseases caused by the abnormal protein kinases.

13. Use according to claim 12, wherein the protein kinases are VEGFR2, PDGFR- β , KIT, AURORA-B, FGFR2, SRC, JAK2 or P38- α .


25

14. Use according to claim 12, wherein the protein kinases are VEGFR2, KIT or PDGFR- β .

15. A pharmaceutical composition, comprising an effective amount of the compound and a pharmaceutically acceptable salt or prodrug thereof according to any one of claims 1-6.

16. The pharmaceutical composition according to claim 15, wherein the composition is an ophthalmic preparation.

5 17. An intermediate compound as represented by formula II:




II

wherein R_4 , R_5 and R_6 are each independently selected from H, halogen, C1-6 alkyl or halogen substituted alkyl, R_7 is selected from H, C1-6 alkyl or halogen.

10

18. An intermediate compound as represented by formula II:




II

wherein R_4 , R_5 and R_6 are each independently selected from halogen, C1-2 alkyl or halogen

15 substituted alkyl, R_7 is selected from H or halogen.

19. An intermediate compound as represented by formula II:



II

20 wherein R_4 , R_5 and R_6 are the same, and are selected from F or Cl; and R_7 is H.